肿瘤内大肠杆菌与晚期非小细胞肺癌患者单药免疫检查点抑制生存率提高相关

文章预览

SCI 16 August 2024 Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer （IF: JCO., 42.1） Elkrief A, Montesion M, Sivakumar S, Hale C, Bowman AS, Begüm Bektaş A, Bradic M, Kang W, Chan E, Gogia P, Manova-Todorova K, Mata DA, Egger JV, Rizvi H, Socci ND, Kelly DW, Rosiek E, Meng F, Tam G, Fan N, Drilon A, Yu HA, Riely GJ, Rekhtman N, Quintanal Villalonga Á, Dogan S, Bhanot U, Gönen M, Loomis B, Hellmann MD, Schoenfeld AJ, Ladanyi M, Rudin CM, Vanderbilt CM. Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Jul 22:JCO2301488.  CORRESPONDING AUTHOR ：Charles M. Rudin, MD, PhD; e-mail: rudinc@mskcc.org. PURPOSE 目的 The impact of the intratumoral microbiome on immune checkpoint inhibitor (ICI) efficacy in patients with non–small-cell lung c ………………………………